Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and sells small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (doing business as Gyre Pharmaceuticals Co., Ltd.), in the People's Republic of China (PRC), and through its U.S. operations based in San Diego, California. In the PRC, Gyre Therapeutics has developed and commercialized ETUARY® (pirfenidone) for fibrotic diseases, which has generated consistent revenue and established the company as a leading participant in treating pulmonary fibrosis. The company has expanded into the United States to advance the clinical development of its pipeline, including F351 (Hydronidone), its lead product candidate for liver fibrosis. Gyre Therapeutics' strategy involves using its existing commercial portfolio to support and reduce risk for late-stage product candidates, extending approved products to treat additional conditions, and creating a diverse pipeline for significant unmet medical needs in fibrosis and related inflammatory diseases. On March 2, 2026, Gyre Therapeutics entered into a Merger Agreement with Cullgen Inc. and Helix Merger Sub Corp., a wholly owned subsidiary of Gyre, under which Merger Sub will merge with Cullgen, with Cullgen becoming a wholly owned subsidiary of Gyre.